NovaBay Pharmaceuticals, Inc. Form SC 13G July 05, 2011

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

NovaBay Pharmaceuticals, Inc. (Name of Issuer)

Common Stock, par value \$0.01 per share (Title of Class of Securities)

66987P102 (CUSIP Number)

June 29, 2011 (Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

"Rule 13d-1(b) xRule 13d-1(c) "Rule 13d-1(d)

(Page 1 of 12 Pages)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

13G

Page 2 of 12 Pages

1	NAMES OF REPORTING PE	RSONS	
	Kingsbrook Opportunities Mas	ter Fund LP	
2	CHECK THE APPROPRIATE	BOX IF A MEMBER OF A GROUP	(a) "
			(b) x
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Cayman Islands		
	5 SOLE VOTING	POWER	
NUMBER OF	- 0 -		
SHARES	6 SHARED VOT	ING POWER	
BENEFICIALLY	2,800,000 share	s of Common Stock	
OWNED BY	Warrants to pure	chase up to 2,100,000 shares of Common	Stock (See Item 4)*
EACH	7 SOLE DISPOSI	TIVE POWER	
REPORTING	- 0 -		
PERSON WITH	8 SHARED DISP	OSITIVE POWER	
TERSON WITH		s of Common Stock	
	•	chase up to 2,100,000 shares of Common	
9	AGGREGATE AMOUNT BE	NEFICIALLY OWNED BY EACH REP	ORTING PERSON
	2,800,000 shares of Common S		
		00,000 shares of Common Stock (See Ite	
10		EGATE AMOUNT IN ROW (9) EXCLU	JDES "
	CERTAIN SHARES		
11		ESENTED BY AMOUNT IN ROW (9)	
	9.9% (See Item 4)*		
12	TYPE OF REPORTING PERS	ON	
	PN		

^{*} As described in Item 4, the warrants are subject to a 9.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of the warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

13G

Page 3 of 12 Pages

1	NAMES OF REPORTING PERSONS		
	Kingsbrook Opportunities GP LLC		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) "	
		(b) x	
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware		
	5 SOLE VOTING POWER		
NUMBER OF	- 0 -		
NUMBER OF	6 SHARED VOTING POWER		
SHARES BENEFICIALLY	2,800,000 shares of Common Stock		
OWNED BY	Warrants to purchase up to 2,100,000 shares of Common	Stock (See Item 4)*	
EACH	7 SOLE DISPOSITIVE POWER		
REPORTING	- 0 -		
PERSON WITH	SHARED DISPOSITIVE POWER		
rekson wiiii	2,800,000 shares of Common Stock		
	Warrants to purchase up to 2,100,000 shares of Common	Stock (See Item 4)*	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REP	ORTING PERSON	
	2,800,000 shares of Common Stock		
	Warrants to purchase up to 2,100,000 shares of Common Stock (See Iter	m 4)*	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLU	DES "	
	CERTAIN SHARES		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	9.9% (See Item 4)*		
12	TYPE OF REPORTING PERSON		
	00		

^{*} As described in Item 4, the warrants are subject to a 9.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of the warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

13G

Page 4 of 12 Pages

1 NAMES OF REPORTING PERSONS	
Kingsbrook Partners LP	
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o	
(b) x	
3 SEC USE ONLY	
4 CITIZENSHIP OR PLACE OF ORGANIZATION	
Delaware	
5 SOLE VOTING POWER	
NUMBER OF COULD NOT NO WED	
SHARES 6 SHARED VOTING POWER	
BENEFICIALLY 2,800,000 shares of Common Stock	
OWNED BY OWNED BY OWNED BY OWNED BY OWNED BY OWNED BY	Item 4)*
EACH 7 SOLE DISPOSITIVE POWER	
REPORTING OF SHAPED DISPOSITIVE POWER	
PERSON WITH: 8 SHARED DISPOSITIVE POWER	
2,800,000 shares of Common Stock	
Warrants to purchase up to 2,100,000 shares of Common Stock (See	
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PL	ERSON
2,800,000 shares of Common Stock	
Warrants to purchase up to 2,100,000 shares of Common Stock (See Item 4)*	
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES	••
CERTAIN SHARES	
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
9.9% (See Item 4)*	
12 TYPE OF REPORTING PERSON	
PN	

^{*} As described in Item 4, the warrants are subject to a 9.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of the warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

13G

Page 5 of 12 Pages

1	NAMES OF REPORTING PERSONS		
	Ari Storch		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) o	
		(b) x	
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
	United States		
	5 SOLE VOTING POWER		
NILLIANDED OF	- 0 -		
NUMBER OF SHARES	6 SHARED VOTING POWER		
BENEFICIALLY	2,800,000 shares of Common Stock		
OWNED BY	Warrants to purchase up to 2,100,000 shares of Common	Stock (See Item 4)*	
EACH	7 SOLE DISPOSITIVE POWER		
2.1011	- 0 -		
REPORTING PERSON WITH	X YHARHIIIINPUNIIIVH PUWHR		
rekson with	2,800,000 shares of Common Stock		
	Warrants to purchase up to 2,100,000 shares of Common	Stock (See Item 4)*	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REP	ORTING PERSON	
	2,800,000 shares of Common Stock		
	Warrants to purchase up to 2,100,000 shares of Common Stock (See Iter	m 4)*	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLU	DES "	
	CERTAIN SHARES		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	9.9% (See Item 4)*		
12	TYPE OF REPORTING PERSON		
	IN		

^{*} As described in Item 4, the warrants are subject to a 9.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of the warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

13G

Page 6 of 12 Pages

1	NAMES OF I	REPORTING PERSONS	
	Adam J. Chill		
2	CHECK THE	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) o
			(b) x
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
United States			
	5	SOLE VOTING POWER	
NUMBER OF		- 0 -	
	6	SHARED VOTING POWER	
SHARES BENEFICIALLY	V.	2,800,000 shares of Common Stock	
OWNED BY	I	Warrants to purchase up to 2,100,000 shares of Common	Stock (See Item 4)*
EACH	7	SOLE DISPOSITIVE POWER	
REPORTING		- 0 -	
PERSON WITH	. 8	SHARED DISPOSITIVE POWER	
rekson with	L.	2,800,000 shares of Common Stock	
		Warrants to purchase up to 2,100,000 shares of Common	Stock (See Item 4)*
9	AGGREGAT	E AMOUNT BENEFICIALLY OWNED BY EACH REP	ORTING PERSON
	2,800,000 sha	res of Common Stock	
	Warrants to p	urchase up to 2,100,000 shares of Common Stock (See Iter	m 4)*
10	CHECK BOX	I IF THE AGGREGATE AMOUNT IN ROW (9) EXCLU	DES "
	CERTAIN SH	HARES	
11	PERCENT O	F CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	9.9% (See Iter	m 4)*	
12	TYPE OF RE	PORTING PERSON	
	IN		

^{*} As described in Item 4, the warrants are subject to a 9.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of the warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

13G

Page 7 of 12 Pages

NAMES OF R	EPORTING PERSONS	
Scott Wallace		
CHECK THE	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) o
		(b) x
SEC USE ONLY		
CITIZENSHIP OR PLACE OF ORGANIZATION		
United States		
5	SOLE VOTING POWER	
	- 0 -	
6	SHARED VOTING POWER	
	2,800,000 shares of Common Stock	
	Warrants to purchase up to 2,100,000 shares of Common	Stock (See Item 4)*
7	SOLE DISPOSITIVE POWER	
	- 0 -	
. 8	SHARED DISPOSITIVE POWER	
• ,	2,800,000 shares of Common Stock	
,	Warrants to purchase up to 2,100,000 shares of Common	Stock (See Item 4)*
AGGREGATE	E AMOUNT BENEFICIALLY OWNED BY EACH REP	ORTING PERSON
2,800,000 share	es of Common Stock	
Warrants to pur	rchase up to 2,100,000 shares of Common Stock (See Iter	m 4)*
CHECK BOX	IF THE AGGREGATE AMOUNT IN ROW (9) EXCLU	DES "
CERTAIN SHA	ARES	
PERCENT OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)	
9.9% (See Item	n 4)*	
TYPE OF REP	PORTING PERSON	
IN		
	Scott Wallace CHECK THE SEC USE ONI CITIZENSHIP United States 5 6 Y 7 8 AGGREGATE 2,800,000 shar Warrants to pu CHECK BOX CERTAIN SH PERCENT OF 9.9% (See Item TYPE OF REF	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION United States 5 SOLE VOTING POWER - 0 - 6 SHARED VOTING POWER 2,800,000 shares of Common Stock Warrants to purchase up to 2,100,000 shares of Common 7 SOLE DISPOSITIVE POWER - 0 - 8 SHARED DISPOSITIVE POWER 2,800,000 shares of Common Stock Warrants to purchase up to 2,100,000 shares of Common AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REP 2,800,000 shares of Common Stock Warrants to purchase up to 2,100,000 shares of Common Stock Warrants to purchase up to 2,100,000 shares of Common Stock CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLU CERTAIN SHARES PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9% (See Item 4)* TYPE OF REPORTING PERSON

^{*} As described in Item 4, the warrants are subject to a 9.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of the warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

13G

Page 8 of 12 Pages

Item 1 (a). NAME OF ISSUER.

The name of the issuer is NovaBay Pharmaceuticals, Inc. (the "Company").

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

The Company's principal executive offices are located at 5980 Horton Street, Suite 550, Emeryville, CA 94608.

Item 2 (a). NAME OF PERSON FILING:

This statement is filed by:

(i)	Kingsbrook Opportunities Master Fund LP, a Cayman Islands limited
	partnership (the "Kingsbrook Fund"), with respect to the Common Stock (as
	defined below) directly held by it;

(ii) Kingsbrook Opportunities GP LLC, a Delaware limited liability company (the "General Partner"), which serves as the general partner of the Kingsbrook Fund, with respect to the Common Stock directly held by the Kingsbrook Fund;

(iii) Kingsbrook Partners LP, a Delaware limited partnership (the "Investment Manager"), which serves as the investment manager to the Kingsbrook Fund, with respect to the Common Stock directly held by the Kingsbrook Fund;

(iv) Mr. Ari Storch ("Mr. Storch"), who serves as senior managing member to the General Partner and KB GP LLC, the general partner of the Investment Manager, with respect to the Common Stock directly held by the Kingsbrook Fund;

(v) Mr. Adam J. Chill ("Mr. Chill"), who serves as managing member to the General Partner and KB GP LLC, the general partner of the Investment Manager, with respect to the Common Stock directly held by the Kingsbrook Fund; and

(vi) Mr. Scott Wallace ("Mr. Wallace"), who serves as managing member to the General Partner and KB GP LLC, the general partner of the Investment Manager, with respect to the Common Stock directly held by the Kingsbrook Fund.

The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form SC 13G

The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

The address of the business office of each of the Reporting Persons is 590 Madison Avenue, 27th Floor, New York, New York 10022.

13G

Page 9 of 12 Pages

Item 2(c). CITIZENSHIP:

The Kingsbrook Fund is a Cayman Islands limited partnership. The General Partner is a Delaware limited liability company. The Investment Manager is a Delaware limited partnership. Messrs. Storch, Chill and Wallace are each United States citizens.

Item 2(d). TITLE OF CLASS OF SECURITIES:

Common Stock, par value \$0.01 per share, (the "Common Stock").

Item 2(e). CUSIP NUMBER:

66987P102

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a) "Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780);
- (b) "Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) "Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) "Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) "Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) "Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) "Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) "Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) "Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
- (j) "Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
- (k) "Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

13**G**

Page 10 of 12 Pages

Item 4. OWNERSHIP.

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

The Company's Prospectus filed pursuant to Rule 424(b)(5) on June 29, 2011, indicates that the total number of outstanding shares of Common Stock upon completion of the offering made pursuant to such Prospectus is 28,100,430. The percentages used herein and in the rest of the Schedule 13G are based upon such number of shares of Common Stock outstanding. The percentages set forth in Row 11 of the cover page for each Reporting Person is based on the Company's outstanding Common Stock and assumes the partial exercise of the warrants reported herein (the "Reported Warrants") up to the Blocker (as defined below). Pursuant to the terms of the Reported Warrants, the Kingsbrook Fund cannot exercise any of the Reported Warrants unless the Reporting Persons would not beneficially own, immediately after any such exercise, more than 9.99% of the outstanding shares of Common Stock (the "Blocker"). As of the date hereof, each of the Reporting Persons may be deemed the beneficial owner of 2,800,000 shares of Common Stock directly held by the Kingsbrook Fund as well as the number of shares of Common Stock underlying the Reported Warrants that are issuable without violating the Blocker.

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

Not applicable.

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Not applicable.

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

Not applicable.

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not applicable.

Item 9. NOTICE OF DISSOLUTION OF GROUP.

Not applicable.

Item 10. CERTIFICATION.

Each of the Reporting Persons hereby makes the following certification:

Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form SC 13G

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

13G

Page 11 of 12 Pages

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: July 5, 2011

KINGSBROOK OPPORTUNITIES MASTER FUND

LP

By: Kingsbrook Opportunities GP LLC, its general

partner

/s/ Adam J. Chill

Name: Adam J. Chill Title: Managing Member

KINGSBROOK OPPORTUNITIES GP LLC

/s/ Adam J. Chill

Name: Adam J. Chill Title: Managing Member

KINGSBROOK PARTNERS LP By: KB GP LLC, its general partner

/s/ Adam J. Chill

Name: Adam J. Chill Title: Managing Member

/s/ Ari Storch Ari Storch

/s/ Adam J. Chill Adam J. Chill

/s/ Scott Wallace Scott Wallace

13G

Page 12 of 12 Pages

EXHIBIT 1

JOINT ACQUISITION STATEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: July 5, 2011

KINGSBROOK OPPORTUNITIES MASTER FUND

LP

By: Kingsbrook Opportunities GP LLC, its general

partner

/s/ Adam J. Chill

Name: Adam J. Chill Title: Managing Member

KINGSBROOK OPPORTUNITIES GP LLC

/s/ Adam J. Chill

Name: Adam J. Chill Title: Managing Member

KINGSBROOK PARTNERS LP By: KB GP LLC, its general partner

/s/ Adam J. Chill

Name: Adam J. Chill Title: Managing Member

/s/ Ari Storch Ari Storch

/s/ Adam J. Chill Adam J. Chill

/s/ Scott Wallace

Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form SC 13G
Scott Wallace